If you have had a diagnosis of IgAN verified by a biopsy taken within the last 10 years, you may qualify for a clinical trial

The clinical trial will evaluate the safety and how the body and immune system respond to an investigational medication called BION-1301*, a potential treatment for patients diagnosed with IgAN. There are currently no FDA/MHRA approved treatments for IgAN, an autoimmune disease. BION-1301 has the potential to work by decreasing the amount of autoimmune proteins in your kidney that can lead to or worsen IgAN.

BION-1301 will be administered subcutaneously to all patients for a total treatment period of 52 weeks.

YOU MAY BE ELIGIBLE IF:

• You are male or female and 18 years or older at screening.
• You have had a biopsy within the last 10 years that confirmed you have IgAN.
• Other criteria apply.

If you are interested in this trial and to find out more, please visit ClinicalTrials.gov (Identifier: NCT03945318; Part 3 of this trial is enrolling patients with IgAN) for your nearest site contact and location information.

* An investigational drug is a drug that has not yet been approved by regulatory authorities. Efficacy and safety have not been established. There is no guarantee that it will become commercially available for the use(s) under investigation.